Fundamental Analysis of EYENOVIA INC(NASDAQ:EYEN) stock

Fundamental Rating

We assign a fundamental rating of 1 out of 10 to EYEN. EYEN was compared to 194 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of EYEN have multiple concerns. While showing a medium growth rate, EYEN is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year EYEN has reported negative net income.

EYEN had a negative operating cash flow in the past year.

In the past 5 years EYEN always reported negative net income.

In the past 5 years EYEN always reported negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -196.28%, EYEN is doing worse than 90.63% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-196.28%
ROE	N/A
ROIC	N/A

ROA(3y)-75.11%

ROA(5y)-85.52%

ROE(3y)-175.98%

ROE(5y)-167.48%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

EYEN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

EYEN does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, EYEN has more shares outstanding

Compared to 5 years ago, EYEN has more shares outstanding

EYEN has a worse debt/assets ratio than last year.

2.2 Solvency

EYEN has an Altman-Z score of -18.30. This is a bad value and indicates that EYEN is not financially healthy and even has some risk of bankruptcy.

EYEN's Altman-Z score of -18.30 is on the low side compared to the rest of the industry. EYEN is outperformed by 85.42% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-18.3

ROIC/WACCN/A

WACC12.58%

2.3 Liquidity

A Current Ratio of 0.46 indicates that EYEN may have some problems paying its short term obligations.

Looking at the Current ratio, with a value of 0.46, EYEN is doing worse than 95.83% of the companies in the same industry.

A Quick Ratio of 0.27 indicates that EYEN may have some problems paying its short term obligations.

With a Quick ratio value of 0.27, EYEN is not doing good in the industry: 96.35% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Current Ratio	0.46
Quick Ratio	0.27

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

EYEN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -10.61%.

Measured over the past years, EYEN shows a very negative growth in Revenue. The Revenue has been decreasing by -87.63% on average per year.

EPS 1Y (TTM)-10.61%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%38.89%

Revenue 1Y (TTM)N/A

Revenue growth 3Y-87.63%

Revenue growth 5YN/A

Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, EYEN will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.78% on average per year.

The Revenue is expected to grow by 202.06% on average over the next years. This is a very strong growth

EPS Next Y1.55%

EPS Next 2Y9.46%

EPS Next 3Y6.74%

EPS Next 5Y17.78%

Revenue Next Year340.72%

Revenue Next 2Y368.28%

Revenue Next 3Y329.74%

Revenue Next 5Y202.06%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EYEN. In the last year negative earnings were reported.

Also next year EYEN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y9.46%

EPS Next 3Y6.74%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for EYEN!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

EYENOVIA INC

NASDAQ:EYEN (11/15/2024, 8:06:08 PM)

After market: 0.103 +0 (+1.08%)

0.1019

-0.24 (-70.04%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap8.80M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-196.28%
ROE	N/A
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	0.46
Quick Ratio	0.27
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)-10.61%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y1.55%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3Y-87.63%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

EYENOVIA INC (EYEN)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens